60 Participants Needed

Rimegepant for Migraine

(RIM Trial)

YT
Overseen ByYemisrach Tadesse
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman ≥ 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress let-down headache.

Who Is on the Research Team?

JA

Jessica Ailani, MD

Principal Investigator

MedStar's Georgetown University Hospital

Are You a Good Fit for This Trial?

This trial is for adults over 18 in the US with a history of migraines triggered by specific activities like exercise, moderate alcohol consumption, air travel up to 12 hours, sexual activity, fasting up to 24 hours, or stress. Participants should have had migraines for at least a year and experience them frequently enough to distinguish from other headaches.

Inclusion Criteria

My headaches or migraines started before I turned 50.
I am 18 years old or older.
My migraines last between 4 to 72 hours without treatment.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive preemptive treatment with Rimegepant for predictable trigger-induced migraine

2 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 months

What Are the Treatments Tested in This Trial?

Interventions

  • Rimegepant

Trial Overview

The study tests Rimegepant 75 MG as a preemptive treatment for migraines induced by predictable triggers. It's an open-label trial where all participants know they're receiving the medication and are monitored at Medstar Georgetown Headache Center.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Rimegepant 75 MGExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Medstar Health Research Institute

Lead Sponsor

Trials
202
Recruited
187,000+

Pfizer

Industry Sponsor

Trials
4,712
Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni profile image

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University